NBDC Research ID: hum0194.v1

 

SUMMARY

Aims: To study the molecular mechanisms of drug resistance in lung cancer patients by using of their tumor cells

Methods: Target Capture Sequencing

Participants/Materials: tumor tissues from ROS1-rearranged non-small cell lung cancer patients

 

Dataset IDType of DataCriteriaRelease Date
JGAS000189 NGS (Target Capture) Controlled-access (Type I) 2020/05/11

*Release Note

*Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more

 

MOLECULAR DATA

JGAS000189
Participants/Materials Lung adenocarcinoma (ICD10: C34): 2 cases
Targets Target Capture
Target Loci for Capture Methods

ABL1, AKT1, AKT3, ALK, APC, ATM, AXL, BCL2L11,

BRAF, BRCA1, BRCA2, CCND1, CDH1, CD274, CDKN2A,

CFTR, CREBBP, CSF1R, CTNNA3, CTNNB1, CUL3, DCC,

EGFR, EPHA2, EPHA7, ERBB2, ERBB3, ERBB4, FBXW7,

FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXA1, FOXP1,

GNA11, GNAQ, GNAS, GRM3, HGF, HNF1A, HRAS,

IDH1, IDH2, IGF1R, JAK2, JAK3, KDR, KEAP1, KIT,

KLF4, KRAS, MAP2K1, MAP2K2, MC1R, MCL1, MED12,

MERTK, MET, MITF, MLH1, MLL2, MLL3, MPL, MSH2,

MSH6, MTOR, MYC, MYCN, NF1, NF2, NFE2L2, NOTCH1,

NOTCH2, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA,

PIK3C2B, PIK3CA, PIK3CG, PMS2, PTCH1, PTEN, PTPN11,

RAC1, RAC2, RB1, RET, ROCK2, ROS1, SH2B3, SLIT2,

SMAD4, SMARCA4, SMARCB1, SMO, SOX2, SPOP,

SRC, STK11, TP53, TRAF7, TSC1, TSC2, VHL
Platform Illumina [MiSeq]
Library Source DNAs extracted from tumor tissues
Cell Lines -
Library Construction (kit name) Agilent HaloPlex HS Custom Kits
Fragmentation Methods Restriction enzyme digestion (included in the above library construction kit)
Spot Type Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers) 150 bp
Japanese Genotype-phenotype Archive Dataset ID JGAD000272
Total Data Volume 128 MB (bam, vcf [ref: hg38])
Comments (Policies) NBDC policy

 

DATA PROVIDER

Principal Investigator: Ryohei Katayama

Affiliation: Japanese Foundation for Cancer Research

Project / Group Name: Div of Exp Chemother, Cancer Chemotherapy Center

URL： https://www.jfcr.or.jp/english/chemotherapy/department/fundamental/index.html

Funds / Grants (Research Project Number):

NameTitleProject Number
KAKENHI Grant-in-Aid for Scientific Research (B) Drug resistance mechanisms and therapeutic strategies in rare driver oncogene positive cancers 16H04715
KAKENHI Grant-in-Aid for Scientific Research (B) Molecular mechanisms of drug tolerant persister cells emergence after molecular target therapy in lung cancer 19H03524
KAKENHI Grant-in-Aid for Scientific Research (A) Molecular analysis of acquired resistance to targeted therapies and search for overcoming drugs 15H02368
KAKENHI Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area) Integrated analysis and regulation of cellular diversity for disease treatment 17H06327
Project for Cancer Research and Therapeutic Evolution (P-CREATE), Japan Agency for Medical Research and Development (AMED) Development of combined strategy for treatment of drug-insensitive cancers with advanced technologies in interdisciplinary research areas JP19cm0106203
Practical Research for Innovative Cancer Control, Japan Agency for Medical Research and Development (AMED) Mechanisms of checkpoint inhibitor resistance through secretable immunosuppressive variants JP19ck0106472

 

PUBLICATIONS

TitleDOIDataset ID
1 The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models doi: 10.1038/s41467-019-11496-z JGAD000272
2

 

USRES (Controlled-access Data)

Principal InvestigatorAffiliationCountry/RegionResearch TitleData in Use (Dataset ID)Period of Data Use
Hirofumi Nakaoka Department of Cancer Genome Research, Sasaki Institute Japan Genetic analysis of lung cancer JGAD000272 2022/08/06-2023/03/31